Target intelligence / Profile preview

Epstein-Barr virus nuclear antigen 3A (EBNA-3A)

Target
EBNA-3A
Molecular classification
Transcription factor, Other
01

Overview

Epstein-Barr virus nuclear antigen 3A (EBNA-3A) is a latent viral protein encoded by the Epstein-Barr virus (EBV) that plays an essential role in the immortalization and continuous proliferation of primary human B lymphocytes. As a key transcriptional regulator, EBNA-3A does not bind DNA directly but is tethered to host genomic sites through interactions with cellular transcription factors such as RBP-Jk (CBF1) and BATF complexes. It cooperates with other EBV latent proteins, particularly EBNA-3C, to epigenetically silence tumor suppressor genes and cell cycle inhibitors, including CDKN2A (p16INK4a/p14ARF), CDKN1A (p21WAF1/CIP1), and BCL2L11 (Bim), thereby preventing apoptosis and senescence. EBNA-3A is strongly implicated in the pathogenesis of EBV-associated malignancies, such as Burkitt's lymphoma, Hodgkin's lymphoma, and post-transplant lymphoproliferative disorders (PTLD). While there are currently no approved small molecules that directly bind and inhibit EBNA-3A, therapeutic strategies under investigation target its downstream epigenetic and survival pathways using EZH2 inhibitors, DNA methyltransferase inhibitors, HDAC inhibitors, and proteasome inhibitors.

Other names
EBNA3AEpstein-Barr nuclear antigen 3AEBV nuclear antigen 3AEpstein-Barr nuclear antigen 3EBNA-3EBNA3
02

Mechanism of action

No approved drugs directly target EBNA-3A. Experimental strategies focus on inhibiting downstream epigenetic silencing (e.g., using EZH2 inhibitors like GSK126, DNA methyltransferase inhibitors like 5-azacytidine, or HDAC inhibitors like vorinostat) or inducing proteasomal degradation of viral/cellular survival factors (e.g., using bortezomib).

03

Biological functions

Immune responseCell cycleApoptosisCell proliferationOther
04

Disease associations

InfectionCancer
05

Safety considerations

Off-target epigenetic effects of indirect therapiesSystemic toxicity of HDAC or proteasome inhibitorsPotential for viral reactivation or lytic cycle inductionImmunosuppression
06

Biomarkers

EBV DNA loadEBNA-3A expressionBim (BCL2L11) expressionp21WAF1/CIP1 expressionSTK39 expression

Beyond the preview

Go deeper on Epstein-Barr virus nuclear antigen 3A (EBNA-3A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epstein-Barr virus nuclear antigen 3A (EBNA-3A).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call